Clare Grieve
Overview
Explore the profile of Clare Grieve including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar A, Soumerai J, Soumerai J, Abramson J, Barnes J, Caron P, et al.
Blood
. 2024 Oct;
145(5):497-507.
PMID: 39437708
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients...
2.
Grieve C, Joseph A, Drullinsky P, Zelenetz A, Hamlin P, Kumar A
Leuk Lymphoma
. 2024 Jan;
65(2):235-241.
PMID: 38264906
This dose-finding study evaluated safety of venetoclax plus Bendamustine-Rituximab-Ibrutinib in relapsed/refractory MCL. Six 28-day cycles were administered in a 3 + 3 dose-escalation design. Dose level 1 (DL1) included Bendamustine...
3.
Geistlinger L, Mirzayi C, Zohra F, Azhar R, Elsafoury S, Grieve C, et al.
Nat Biotechnol
. 2023 Sep;
42(5):790-802.
PMID: 37697152
The literature of human and other host-associated microbiome studies is expanding rapidly, but systematic comparisons among published results of host-associated microbiome signatures of differential abundance remain difficult. We present BugSigDB,...
4.
Kumar A, Casulo C, Joffe E, Moskowitz C, Gerecitano J, Moskowitz A, et al.
Leuk Lymphoma
. 2022 Aug;
63(12):2889-2896.
PMID: 35972020
This study evaluated ofatumumab (Ofa), an anti-CD20 monoclonal antibody, alone or with bendamustine (Benda), in transplant-ineligible patients with mantle cell lymphoma. Low-risk patients received Ofa monotherapy. Non-responders received subsequent treatment...
5.
Soumerai J, Mato A, Dogan A, Seshan V, Joffe E, Flaherty K, et al.
Lancet Haematol
. 2021 Nov;
8(12):e879-e890.
PMID: 34826411
Background: We hypothesised that combining zanubrutinib with obinutuzumab and venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetectable...
6.
Kumar A, Casulo C, Advani R, Budde E, Barr P, Batlevi C, et al.
J Clin Oncol
. 2021 Apr;
39(20):2257-2265.
PMID: 33909449
Purpose: To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma. Methods: In this multicenter study with four sequential cohorts, patients received four cycles...